VX-702
|
|
|
- CAS番號.
- 745833-23-2
- 化學(xué)名:
- VX-702
- 別名:
- VX-702
- 英語名:
- VX 702
- 英語別名:
- VX 702;CS-1840;VX702;VX-702;VX 702 USP/EP/BP;(479543-46-9) vx 702;VX-702, 10 mM in DMSO;VX-702,VX702,VX 702,Inhibitor,p38 MAPK,inhibit,Autophagy;2-(2,4-Difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide;6-[(Aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinecarboxamide;3-Pyridinecarboxamide, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-
- CBNumber:
- CB02484952
- 化學(xué)式:
- C19H12F4N4O2
- 分子量:
- 404.32
- MOL File:
- 745833-23-2.mol
- MSDS File:
- SDS
|
VX-702 物理性質(zhì)
- 沸點 :
- 555.2±60.0 °C(Predicted)
- 比重(密度) :
- 1.503
- 貯蔵溫度 :
- -20°C
- 溶解性:
- DMSO (最大 40mg/ml) またはエタノール (最大 2mg/ml) に可溶。
- 外見 :
- 個體
- 酸解離定數(shù)(Pka):
- 10.65±0.50(Predicted)
- 色:
- 白い
- 安定性：:
- 購入日から2年間安定です。この DMSO またはエタノール溶液は、-20°C で 3 か月間保存できます。
- CAS データベース:
- 745833-23-2
| メーカー |
製品番號 |
製品説明 |
CAS番號 |
包裝 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式會社(wako)
|
W01BVI1598-1 |
VX-702 |
745833-23-2 |
1mg |
￥80600 |
2020-09-21 |
購入 |
|
富士フイルム和光純薬株式會社(wako)
|
W01BVI1598-5 |
VX-702 |
745833-23-2 |
5mg |
￥244400 |
2020-09-21 |
購入 |
|
東京化成工業(yè)
|
V0147 |
VX-702 >98.0%(HPLC)
VX-702
>98.0%(HPLC) |
745833-23-2 |
25mg |
￥17000 |
2024-03-01 |
購入 |
|
東京化成工業(yè)
|
V0147 |
VX-702 >98.0%(HPLC)
VX-702
>98.0%(HPLC) |
745833-23-2 |
100mg |
￥51500 |
2024-03-01 |
購入 |
VX-702 化學(xué)特性,用途語,生産方法
外観
白色～ほとんど白色粉末～結(jié)晶
説明
VX-
702 is a third generation inhibitor of p38 mitogen-activated protein (MAP) kinases, binding to both p38α and p38β (Kd = 3.7 and 17 nM, respectively) in an ATP-competitive fashion. It inhibits IL-6, IL-1β, and TNF-α production in LPS-primed blood with IC50 values of 59, 122, and 99 ng/ml, respectively. VX-702, at 1 μM, inhibits activation of p38 in platelets by thrombin, U-46619 , or collagen but does not block platelet aggregation in response to collagen. Although orally active, VX-702 provides only transient suppression of biomarkers of inflammation in ongoing rheumatoid arthritis.
使用
VX-702 is a p38 mitogen-activated protein kinase (MAPK) inhibitor. VX-702 had no effect on platelet aggregation induced by any of the p38 MAPK agonists. VX-702 has potential use in the treatment of inflammation, rheumatoid arthritis and cardiovascular diseases.
VX-702 上流と下流の製品情報
原材料
準(zhǔn)備製品
VX-702 生産企業(yè)
Global( 124)Suppliers
745833-23-2(VX-702)キーワード:
- 745833-23-2
- 6-[(Aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinecarboxamide
- VX 702
- 6-[(Aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinecarboxamide VX-702
- VX 702 6-[(Aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinecarboxamide
- VX702;VX-702
- 2-(2,4-Difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide
- (479543-46-9) vx 702
- CS-1840
- 3-Pyridinecarboxamide, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-
- VX 702 USP/EP/BP
- VX-702,VX702,VX 702,Inhibitor,p38 MAPK,inhibit,Autophagy
- VX-702, 10 mM in DMSO
- VX-702